A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
Authors:
- R KremerRKR Kremer
- D GoltzmanDGD Goltzman
- S A RabbaniS A Rabbani
Open Access
- 1 June 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 91 (6) , 2416-2422
Abstract
We have examined the effects of 1,25 dihydroxyvitamin D3 (1,25[OH]2D3) and a low calcemic analogue EB1089 on parathyroid hormone-related peptide (PTHRP) production and on the development of hypercalcemia in Fischer rats implanted with the Leydig cell tumor H-500. Leydig cell tumors were implanted subcutaneously into male Fischer rats, which received constant infusions intraperitoneally of either 1,25(OH)2D3 (50-200 pmol/24 h), EB1089 (50-400 pmol/24 h), or vehicle for up to 4 wk. A control group of animals received similar infusions without tumor implantation. Plasma calcium, plasma levels of immunoreactive iPTHRP, and tumor PTHRP mRNA levels were determined as well as tumor size, animal body weight, and animal survival time. Non-tumor-bearing animals receiving > 50 pmol/24 h of 1,25(OH)2D3 became hypercalcemic, whereas no significant change in plasma calcium was observed in animals receiving < or = 200 pmol/24 h of EB1089. Tumor-bearing animals receiving vehicle alone or > 50 pmol/24 h of 1,25(OH)2D3 became severely hypercalcemic within 15 d. However, animals treated with low dose 1,25(OH)2D3 and all doses of EB1089 maintained near-normal or normal levels of plasma calcium for up to 4 wk. Additionally, reduced levels of tumor PTHRP mRNA and of plasma iPTHRP were observed compared with controls in both vitamin D- and EB1089-treated rats. Infusion of 50 pmol/24 h of 1,25(OH)2D3 and 200 pmol/24 h of EB1089 significantly reduced tumor volume by the end of experiment. The analogue but not 1,25(OH)2D3 substantially prolonged survival time in tumor-bearing animals with longer survival achieved at the highest dose, 400 pmol/24 h, of EB1089. These studies demonstrate that 1,25(OH)2D3 and a low calcemic vitamin D analogue are potent inhibitors of PTHRP production in vivo. Low calcemic analogues may therefore represent important alternative therapy for malignancy-associated hypercalcemia.Keywords
This publication has 32 references indexed in Scilit:
- Transcriptional Regulation of the Parathyroid Hormone-related Peptide Gene by Glucocorticoids and Vitamin D in a Human C-cell LineJournal of Biological Chemistry, 1989
- The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.Journal of Clinical Investigation, 1989
- A SYNTHETIC ANALOGUE OF VITAMIN D3, 22-OXA-lα,25-DIHYDROXYVITAMIN D3IS A POTENT MODULATOR OF IN VIVO IMMUNOREGULATING ACTIVITY WITHOUT INDUCING HYPERCALCEMIA IN MICEEndocrinology, 1989
- Rat Parathyroid Hormone-Like Peptide: Comparison with the Human Homologue and Expression in Malignant and Normal TissueMolecular Endocrinology, 1989
- pl Bl5: A cDNA Clone of the Rat mRNA Encoding CyclophilinDNA, 1988
- Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy.Proceedings of the National Academy of Sciences, 1988
- Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone.Journal of Clinical Investigation, 1987
- Parathyroid hormone-related protein purified from a human lung cancer cell line.Proceedings of the National Academy of Sciences, 1987
- N-Terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: Identification of parathyroid hormone-like and parathyroid hormone-unlike domainsBiochemical and Biophysical Research Communications, 1987
- SUPPRESSION OF INVIVO GROWTH OF HUMAN CANCER SOLID TUMOR XENOGRAFTS BY 1,25-DIHYDROXYVITAMIN-D31987